Duodenal ulcer Medical Services in China

A duodenal ulcer is a circumscribed mucosal defect in the first part of the duodenum—the initial segment of the small intestine—extending through the muscularis mucosae into the submucosa. It is a common form of peptic ulcer disease (PUD), distinguished from gastric ulcers by its anatomical location distal to the gastroduodenal junction. Pathogenesis centers on an imbalance between aggressive luminal factors (primarily gastric acid and pepsin) and defensive mucosal mechanisms. The overwhelming majority of cases (>90%) are associated with Helicobacter pylori infection, a gram-negative bacterium that colonizes the gastric antrum and induces chronic active gastritis, disrupts mucosal barrier integrity, and stimulates acid hypersecretion via cytokine-mediated pathways. Nonsteroidal anti-inflammatory drugs (NSAIDs), including low-dose aspirin, independently impair prostaglandin synthesis—critical for mucus and bicarbonate secretion and mucosal blood flow—thereby increasing ulcer risk even in H. pylori-negative individuals. Less common contributors include Zollinger-Ellison syndrome (gastrin-secreting tumors), smoking, severe physiological stress (e.g., major trauma or critical illness), and genetic predisposition (e.g., polymorphisms in IL-1β and TNF-α genes). Epidemiologically, duodenal ulcers affect approximately 5–10% of the global population over a lifetime, with higher prevalence in developing regions due to widespread H. pylori carriage. Incidence peaks between ages 30 and 50, and males are affected 2–3 times more frequently than females. While overall incidence has declined in high-income countries following H. pylori eradication campaigns and NSAID stewardship, it remains prevalent in China, where H. pylori seroprevalence exceeds 50% in adults and regional antibiotic resistance patterns complicate treatment. Key modifiable risk factors include untreated H. pylori infection, regular NSAID or corticosteroid use, cigarette smoking (which delays healing and doubles recurrence risk), excessive alcohol consumption, and chronic psychological stress—though stress alone does not cause ulcers. Untreated or recurrent ulcers significantly impair quality of life: patients commonly report nocturnal epigastric burning or gnawing pain relieved by food or antacids, postprandial discomfort, nausea, early satiety, and hematemesis or melena in complicated cases. Chronic symptoms lead to sleep disruption, reduced work productivity, dietary restrictions, anxiety about bleeding or perforation, and avoidance of social meals—contributing to measurable declines in physical functioning, vitality, and mental health domains on validated QoL instruments like the SF-36. With timely diagnosis—including upper endoscopy (gold standard) and rapid urease testing or stool antigen assays for H. pylori—and evidence-based therapy, most patients achieve complete mucosal healing and sustained remission.

Duodenal ulcers—circumscribed mucosal defects extending through the muscularis mucosae into the submucosa of the duodenal bulb—are predominantly caused by Helicobacter pylori infection (present in >90% of cases) and/or nonsteroidal anti-inflammatory drug (NSAID) use. Less common etiologies include hypersecretory states (e.g., Zollinger-Ellison syndrome), smoking, excessive alcohol intake, and physiological stress. Accurate diagnosis relies on upper gastrointestinal endoscopy with biopsy for H. pylori testing (rapid urease test, histology, or culture) and, when indicated, serum gastrin measurement. Conservative management forms the cornerstone of therapy, emphasizing ulcer healing, symptom relief, eradication of underlying causative factors, and prevention of recurrence and complications—including bleeding, perforation, and gastric outlet obstruction.

Conservative treatment begins with immediate lifestyle and behavioral modification. Patients are advised to discontinue NSAIDs unless absolutely necessary; if continued, co-therapy with a proton pump inhibitor (PPI) is mandatory. Smoking cessation is strongly emphasized, as nicotine impairs mucosal blood flow, delays ulcer healing, and increases recurrence risk by up to 2-fold. Alcohol consumption should be minimized or eliminated due to its direct mucosal irritant effect and synergistic interaction with acid secretion. Dietary adjustments focus on symptom-guided moderation rather than rigid restrictions; while spicy, acidic, or caffeinated foods do not cause ulcers, they may exacerbate dyspepsia in sensitive individuals and warrant individualized avoidance.

Pharmacotherapy is stratified into three interdependent pillars: acid suppression, H. pylori eradication, and mucosal protection. First-line acid suppression employs high-dose PPIs—such as esomeprazole 40 mg once daily, rabeprazole 20 mg twice daily, or pantoprazole 40 mg once daily—for 4–6 weeks. PPIs achieve intragastric pH >4 for >16 hours daily, optimizing conditions for epithelial restitution and reducing pepsin activity. In patients with documented H. pylori infection, standard triple therapy (PPI + amoxicillin 1 g twice daily + clarithromycin 500 mg twice daily for 14 days) remains effective where clarithromycin resistance is <15%. However, due to rising global resistance (>25% in many regions), bismuth quadruple therapy (PPI + bismuth subsalicylate 524 mg four times daily + tetracycline 500 mg four times daily + metronidazole 500 mg three or four times daily for 10–14 days) is increasingly recommended as first-line in high-resistance settings. All regimens require strict adherence and post-treatment confirmation of eradication via urea breath test, stool antigen test, or repeat endoscopy with biopsy at least 4 weeks after antibiotic completion and 2 weeks after PPI discontinuation. For NSAID-induced ulcers without H. pylori, long-term PPI maintenance (e.g., omeprazole 20 mg daily) is indicated if NSAID continuation is unavoidable. Sucralfate (1 g four times daily) may serve as adjunctive mucosal protectant in select cases, particularly where PPIs are contraindicated, though evidence for superiority over PPI monotherapy is lacking.

Surgical intervention is now rare—reserved for life-threatening complications refractory to endoscopic or medical management. Indications include uncontrolled arterial bleeding despite high-dose IV PPIs and endoscopic hemostasis (e.g., epinephrine injection, thermal coagulation, clip application), free perforation with peritonitis, or fibrotic gastric outlet obstruction unresponsive to endoscopic balloon dilation. Procedures include laparoscopic or open truncal vagotomy with antrectomy (to reduce acid output and remove G-cell-rich antrum), highly selective vagotomy (preserving gastric motility), or pyloroplasty combined with vagotomy. Emergency surgery carries significant morbidity (wound infection, dumping syndrome, diarrhea, bile reflux gastritis) and mortality (3–10% in elderly/comorbid patients); thus, it is strictly reserved for failure of definitive medical and endoscopic strategies.

Treatment in China offers distinct advantages rooted in integrated clinical infrastructure, pharmacovigilance, and health policy. Chinese gastroenterology centers maintain nationwide H. pylori antimicrobial resistance surveillance networks, enabling region-specific, evidence-based empiric regimens—critical given regional variation in clarithromycin (>30%) and metronidazole (>60%) resistance. Domestic production ensures reliable access to high-quality generic PPIs and bismuth compounds at low cost, enhancing treatment adherence. Endoscopic capabilities are exceptionally advanced: >95% of tertiary hospitals perform high-definition narrow-band imaging (NBI) and magnifying endoscopy for precise ulcer characterization and early neoplasia detection. Moreover, China’s National Reimbursement Drug List includes all first-line H. pylori therapies, reducing out-of-pocket burden. Traditional Chinese Medicine (TCM) adjuncts—such as Weikangling granules or Huangqin Tang—are rigorously evaluated in randomized controlled trials and used alongside PPIs to alleviate residual symptoms (e.g., bloating, nausea) and modulate gut microbiota, though they are never substituted for evidence-based eradication therapy.

Recovery advice emphasizes structured follow-up and sustained risk mitigation. Patients should undergo repeat endoscopy only if alarm features persist (e.g., weight loss, anemia, persistent vomiting) or if initial ulcer was large (>2 cm), irregular, or associated with bleeding—otherwise, clinical assessment suffices. Symptom resolution typically occurs within 1–2 weeks of PPI initiation; however, full mucosal healing requires 4–6 weeks. Patients must complete the entire antibiotic course—even if asymptomatic—to prevent resistance emergence. Long-term strategies include annual H. pylori screening for household contacts, avoidance of NSAIDs or use of COX-2 inhibitors with PPI prophylaxis in high-risk individuals, and regular monitoring of iron/ferritin levels in those with prior bleeding ulcers. Stress management techniques (mindfulness, cognitive-behavioral therapy) are encouraged, as chronic psychological stress correlates with delayed healing independent of acid output. Finally, patients should seek urgent evaluation for hematemesis, melena, sudden severe abdominal pain, or syncope—signs of acute complication requiring emergent endoscopy or surgery. With contemporary protocols, >95% of duodenal ulcers heal completely within 8 weeks, and recurrence rates fall below 5% at 1 year following successful H. pylori eradication.